|
|
Montrouge, France, October 31, 2023
DBV Technologies Receives Requested Feedback
from FDA on Protocol Design Elements for COMFORT
Safety Studies and Reports Third Quarter 2023
Financial Results
• DBV has received written feedback from the U.S. Food and Drug
Administration FDA clarifying design elements for both the
COMFORT Toddlers and COMFORT Children supplemental... Lire le communiqué |
|
| |
|
| |
|
|
Montrouge, France, le 27 octobre 22h30 CET
DBV Technologies présente ses résultats financiers du
troisième trimestre 2023 et fait le point sur ses
activités
DBV Technologies Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market :
DBVT, une société biopharmaceutique au stade clinique, a annoncé aujourd’hui
que la société organisera une conférence téléphonique et un... Lire le communiqué |
|
| |
|
| |
|
|
Montrouge, France, October 27, 2023
DBV Technologies to Report Third Quarter 2023
Financial Results and Business Update
DBV Technologies Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market:
DBVT, a clinicalstage biopharmaceutical company, today announced that the
Company will host a conference call and live audio webcast on Tuesday, October
31st, at 5:00 p.m. ET to review third... Lire le communiqué |
|
| |
|
| |
|
|
Montrouge, France, October 16, 2023
DBV Technologies Announces Appointment of
Virginie Boucinha as Chief Financial Officer
DBV Technologies Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market:
DBVT, a clinicalstage biopharmaceutical company, today announced the
appointment of Virginie Boucinha as its Chief Financial Officer, effective... Lire le communiqué |
|
| |
|
| |
|
|
Monthly information regarding the total number of voting rights and
total number of shares of the Company as of September 30, 2023
Article 22316 of the General Regulations of the Autorité des Marchés Financiers
Market : NYSE Euronext Paris
ISIN Code: FR 0010417345
Date Total number of shares Total number of voting... Lire le communiqué |
|
| |
|
| |
|
|
Information mensuelle relative au nombre total des droits de vote et
d’actions composant le capital social au 30 septembre 2023
Article 22316 du Règlement Général de l’Autorité des Marchés Financiers
Place de cotation : NYSE Euronext Paris
Code ISIN : FR 0010417345
Nombre total
... Lire le communiqué |
|
| |
|
| |
|
|
Montrouge, France, September 5, 2023
DBV Technologies to Participate in Upcoming
Investor Conference
DBV Technologies Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market:
DBVT, a clinicalstage biopharmaceutical company, today announced the
company will participate in the H.C. Wainwright Annual Global Investment
Conference taking place on September 11th −13th in New York, NY. Daniel... Lire le communiqué |
|
| |
|
| |
